Bay Colony Advisory Group Inc d b a Bay Colony Advisors Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,676 shares of the biopharmaceutical company’s stock after buying an additional 392 shares during the quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Regeneron Pharmaceuticals were worth $1,068,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $25,000. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $28,000. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares in the last quarter. Tompkins Financial Corp purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $32,000. Finally, Curat Global LLC purchased a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $513.58 on Thursday. The company has a fifty day simple moving average of $559.88 and a 200-day simple moving average of $645.05. The firm has a market capitalization of $55.45 billion, a price-to-earnings ratio of 13.07, a PEG ratio of 1.86 and a beta of 0.31. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. During the same period in the prior year, the company posted $9.55 EPS. The firm’s revenue was down 3.7% on a year-over-year basis. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.96%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on REGN. Guggenheim reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 1st. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a research report on Monday, June 9th. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating for the company in a research note on Monday, June 2nd. Finally, BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a research note on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.